** Quiksilver Inc. (NYSE:ZQK) was upgraded from Hold to Buy by Brokerage Firm Stifel Nicolaus
Online PR News – 06-November-2012 – Las Vegas, NV – ENZ, Enzo Biochem Inc.
ENZ reported that it was awarded $48.6 million after a federal jury said Life Technologies Corp.'s Applera unit infringed a patent over a way to detect genetic sequences and diagnose human diseases such as cancer. The federal jury in New Haven, Connecticut, rejected Appleras claims that the patent was invalid. The jury also found that Life Technologies sequencing instruments induced its customers to infringe ENZs patent No. 5,449,767. The sales of such instruments are estimated to be $770 million. ENZ will ask for interest that could add tens of millions of dollars to the final damage award. The suit was first filed in 2004 by New York-based Enzo and Yale University. They were demanding royalties on Lifes genetic research and screening. The trial focused on Appleras dRhodamine and BigDye Terminator products used to sequence DNA. The patent, issued in 1995, has since expired. According to ENZ, the verdict could help it resolve cases it filed against other companies including Amersham PLC, Amersham Biosciences, Roche Diagnostics, PerkinElmer, Inc., PerkinElmer Life Sciences, Inc, Molecular Probes, Inc.(now owned by Life Technologies), Orchid Cellmark, Inc. (now owned by Laboratory Corporation of America) and Affymetrix, Inc. ENZ is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and therapeutics through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. More about ENZ at www.enzo.com
ZQK, Quiksilver Inc.
ZQK was upgraded from Hold to Buy by Brokerage Firm Stifel Nicolaus ZQK designs, develops, produces, and distributes apparel, footwear, accessories, and related products More about ZQK at www.quiksilver.com
Read Full Disclaimer at http://stockbling.com/disclaimer